1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers
    Meeting Abstract

    Sanborn, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Gordon, M.; Hauke, R.; Bordoni, R.; Khalil, D.; Rawls, T.; Vitale, L.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER)
    Meeting Abstract

    Nissola, L.; Autio, K.; Bhardwaj, N.; Galsky, M.; Wentzel, K.; Lucey, V.; Selinsky, C.; Perry, C.; Cabanski, C.; Bitton, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • The impact of metastatic sites on checkpoint inhibitor outcomes in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Krieger, P.; Sanchez-Vega, F.; Schultz, N.; Shoushtari, A.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
    Meeting Abstract

    Ma, J.; Klatt, M.; Dundar, F.; Zumbo, P.; Femia, M.; Betel, D.; Scheinberg, D.; Baker, B.; Klebanoff, C.; Chandran, S.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)
    Meeting Abstract

    Msaouel, P.; Siefker-Radtke, A.; Sweis, R.; Mortazavi, A.; Vogelzang, N.; Vaishampayan, U.; Bradley, T.; Bupathi, M.; Nordquist, L.; Shaffer, D.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: Primary analysis after ≥ 15 months of follow-up from JAVELIN Merkel 200, a registrational phase 2 trial
    Meeting Abstract

    D'Angelo, S.; Lebbé, C.; Mortier, L.; Brohl, A.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G.; Hassel, J.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma
    Meeting Abstract

    D'Angelo, S.; Demetri, G.; Van Tine, B.; Druta, M.; Glod, J.; Chow, W.; Tress, J.; DeYoung, M. P.; Hasan, A.; Wu, Y.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Laminar Wash™ AUTO system: A reliable walk-away sample preparation solution for better TIL recovery without centrifugation
    Meeting Abstract

    Kim, I.; Lye, M.; Zappasodi, R.; Schulze, I.; Eberle, C.; Ke, C. Y.; Cheng, K. L.; Kon, I. C.; Pek, R.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design
    Meeting Abstract

    D'Angelo, S.; Blay, J. Y.; Chow, W.; Demetri, G.; Thistlethwaite, F.; Wagner, M.; Loeb, D.; Attia, S.; Razak, A.; Haanen, J.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Blockade of IDO/TDO downstream effectors restricts a Treg-macrophage suppressive axis and resistance to anti-PD-1 therapy
    Meeting Abstract

    Campesato, L.; Budhu, S.; Tchaicha, J.; Gigoux, M.; Cohen, I.; Mangarin, L.; Redmond, D.; Pourpe, S.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save